Shares of USA-based Viking Therapeutics (Nasdaq: VKTX) closed up 28% yesterday and rose a further 6.4% to $68.80 pre-market today, as the company plans to advance its experimental weight loss injection into a late-stage trial earlier than expected.
Viking is one of several small obesity drugmakers hoping to enter the budding weight loss drug industry, which analysts say could grow into a $100 billion market by the end of the decade.
Along with its financial results yesterday, Viking provided an update on its clinical pipeline and other corporate developments.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze